Long-Term Tolerability of Saxagliptin as Add-On Therapy in Type 2 Diabetes (T2D): Pooled Analysis

被引：0
|
作者：
Allen, Elsie
Fleming, Doug
Berglind, Niklas
Donovan, Mark
Ohman, Peter
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1087-P
引用
收藏
页码：A298 / A299
页数：2
相关论文
共 50 条
  • [21] Long-term treatment with testosterone can lead to remission of T2D in hypogonadal men with type 2 diabetes (T2D): results of a urological registry study
    Saad, Farid
    Haider, Ahmad
    Haider, Karim Sultan
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 4) : 256 - 257
  • [22] Time Course of Change in Glycemic Parameters and Weight with Saxagliptin (SAXA) plus Dapagliflozin (DAPA) Dual Add-on to Metformin (MET) Extended Release (XR) in Type 2 Diabetes (T2D)
    Rezvani, Geoffrey
    Chen, Hungta
    Han, Stella
    Mansfield, Traci A.
    DIABETES, 2016, 65 : A298 - A298
  • [23] Quality Measure Outcomes with Dapagliflozin (DAPA) Add-on to Metformin (MET) or Insulin (INS) in Patients with Type 2 Diabetes (T2D)
    Mansfield, Traci
    Bell, Kelly
    Rezvani, Geoffrey
    Shatskov, Alla
    Sheehan, John J.
    DIABETES, 2016, 65 : A307 - A307
  • [24] LINAGLIPTIN AS ADD-ON THERAPY FOR TYPE 2 DIABETES - AN OVERVIEW
    Brown, D. X.
    Choudhury, M.
    Evans, M.
    DRUGS OF TODAY, 2012, 48 (10) : 645 - 654
  • [25] Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
    Pan, C.
    Xing, X.
    Han, P.
    Zheng, S.
    Ma, J.
    Liu, J.
    Lv, X.
    Lu, J.
    Bader, G.
    DIABETES OBESITY & METABOLISM, 2012, 14 (08): : 737 - 744
  • [26] Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8
    Zinman, Bernard
    Aroda, Vanita R.
    Buse, John B.
    Cariou, Bertrand
    Harris, Stewart B.
    Hoff, Soren T.
    Pedersen, Karen Boje
    Tarp-Johansen, Mads Jeppe
    Araki, Eiichi
    DIABETES, 2019, 68
  • [27] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
    Frias, Juan P.
    Gonzalez-Galvez, Guillermo
    Johnsson, Eva K.
    Maaske, Jill
    Peters, Anne
    DIABETES, 2018, 67
  • [28] The long-term effects of pioglitazone (PIO) and glibenclamide (GLB) on plasma lipids in patients with Type 2 diabetes (T2D)
    Clausen, J
    Herz, M
    Johns, D
    Strand, J
    Halse, J
    Madsbad, S
    Eriksson, J
    DIABETOLOGIA, 2003, 46 : A355 - A355
  • [29] Long-term effects of pioglitazone (PIO) and glibenclamide (GLB) on plasma lipids in patients with type 2 diabetes (T2D)
    Meng, T
    Johns, D
    Strand, J
    Halse, J
    Madsbad, S
    Eriksson, J
    Clausen, J
    Herz, M
    DIABETES, 2003, 52 : A135 - A135
  • [30] Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
    Yang, Ai-Yu
    Chen, Hung-Chun
    JOURNAL OF DIABETES RESEARCH, 2022, 2022
12345